Address :
Hidoc Dr. Inc. | Delaware C Corp | 1309 Coffeen Ave. Suite 1200, Sheridan WY, 82801
Phone :
+1-415-463-3094
Email :
anishagadia@hidoc.co
Published Date: 23 Apr 2023
The treatment of chronic thromboembolic pulmonary hypertension with balloon pulmonary angioplasty has an evolving safety profile over the years, from 2013 to 2022, as revealed by an analysis of more than two dozen studies.
Read Full NewsModelling shows fewer cases and deaths with screening starting at age 45 years.
A phase 3 trial examines whether carfilzomib-lenalidomide-dexamethasone maintenance therapy improves disease control compared with lenalidomide alone in patients with multiple myeloma.
Although many surgeons avoid it, nipple-sparing mastectomy after radiation is a feasible alternative to skin-sparing mastectomy and may help preserve patients’ psychological well-being.
1.
Routine breast cancer screening can bring better outcomes for patients
2.
Chemotherapy before surgery helps patients with nose and sinus cancer avoid debilitating eye and bone removal
3.
Achieves a High Disease Control Rate in Head and Neck BCC with Vismodegib-RT Regimen.
4.
Talk About Medication Costs, Bringing Back Touch, and Understanding From Dish Tumors.
5.
According to a study, breast cancer cells work together to physically breach barriers and proliferate.
1.
A Closer Look at Poorly Differentiated Carcinoma: Uncovering its Complexities
2.
The Future is Now: Navigating the Precision Revolution in Oncology Treatment
3.
Innovative Bioengineering Approaches for Erectile Function Recovery After Radical Prostatectomy
4.
Leukemia in Focus: Tools, Trials, and Therapy Strategies for Modern Medical Practice
5.
The Predictive Power of Targeted Radionuclide Therapy in Advanced Breast Cancer
1.
International Lung Cancer Congress®
2.
Genito-Urinary Oncology Summit 2026
3.
Future NRG Oncology Meeting
4.
ISMB 2026 (Intelligent Systems for Molecular Biology)
5.
Annual International Congress on the Future of Breast Cancer East
1.
A New Era in Managing Cancer-Associated Thrombosis
2.
Unmet Needs in ALK Positive NSCLC- The Challenges in the Current Care
3.
Should We Use DARA Up Front As First-Line Therapy in MM? - Part II
4.
Lorlatinib in the Management of 1st line ALK+ mNSCLC (CROWN TRIAL Update) - Conclusion
5.
Efficient Management of First line ALK-rearranged NSCLC - Part III
Address :
Hidoc Dr. Inc. | Delaware C Corp | 1309 Coffeen Ave. Suite 1200, Sheridan WY, 82801
Phone :
+1-415-463-3094
Email :
anishagadia@hidoc.co
© Copyright 2026 Hidoc Dr. Inc.
Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
To get started please enter your email ID
Join to enhance your clinical skills and gain specialized in-depth medical knowledge